A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.

"We thank J.‐Y. Masson (Centre de Recherche en Cancérologie de l'Université Laval, Quebec City Canada) for technical advice and all the clinicians who enrolled patients and participated in the PETACC‐3 trial (see Appendix at: http://jco.ascopubs.org/content/27/19/3117.long), in particular the coordinators D. Cunningham, R. Labianca and E. Van Cutsem. We are grateful to C. Rousseau for editing the manuscript. The Quebec‐Clinical Research Organization in Cancer consortium Q‐CROC (www.qcroc.ca), financed by the Pfizer‐FRSQ Innovation Award, supported this work. E.R.P. is supported by a Doctoral scholarship from the Canadian Institutes of Health Research. S.P.T. is a scholar of the Q‐CROC. M.D. and J.C. were supported in part by the Swiss National Science Foundation (SNF; http://www.snf.ch/E/; Grant No. 320030_135421); Krebsforschung Schweiz (KFS; http://www.krebsforschung.ch/; Grant No. 02697‐08‐2010) and by the Fondation Medic. The Quebec‐Clinical Research Organization in Cancer consortium Q‐CROC (www.qcroc.ca), financed by the Pfizer‐FRSQ Innovation Award, supported this work. E.R.P. is supported by a Doctoral scholarship from the Canadian Institutes of Health Research. S.P.T. is a scholar of the Q‐CROC. M.D. and J.C. were supported in part by the Swiss National Science Foundation (SNF; http://www.snf.ch/E/; Grant No. 320030_135421); Krebsforschung Schweiz (KFS; http://www.krebsforschung.ch/; Grant No. 02697‐08‐2010); and by the Fondation Medic."